NCT07078227 Long-term Follow-up of Depressive Disorders in Psychiatric Care
| NCT ID | NCT07078227 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Skane |
| Condition | Depression |
| Study Type | OBSERVATIONAL |
| Enrollment | 415 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 415 participants in total. It began in 2025-06-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The project investigates long-term prognosis and predictors of treatment outcomes for difficult-to-treat depression in patients in secondary psychiatric care. The current patient cohort was collected in 2012-2021 in the study "Pharmacogenetics in patients with depression with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6". The cohort consists of 415 patients, examined carefully regarding diagnostic assessment and earlier treatment. All participants were also genotyped for the drug metabolizing enzymes CYP2D6 and CYP2C19. Blood samples were stored in biobank for other analyses linked to prognostic markers. The patient cohort will now be followed up with a review of medical records and extraction of register data for a period of 5 years after their participation in the original study. The purpose of the study is to improve treatment and increase knowledge about long-term prognosis in difficult-to-treat depression. This is done by examining symptom profiles, monitoring clinical course and suicidality, and examining prognostic markers.
Eligibility Criteria
Inclusion Criteria: Participation in the study "Pharmacogenetics in depressive patients with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6" Exclusion Criteria: Not wanting to participate in the follow-up study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07078227 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07078227 currently recruiting?
Yes, NCT07078227 is actively recruiting participants. Contact the research team at marie.asp@skane.se for enrollment information.
Where is the NCT07078227 trial being conducted?
This trial is being conducted at Lund, Sweden, Lund, Sweden.
Who is sponsoring the NCT07078227 clinical trial?
NCT07078227 is sponsored by Region Skane. The trial plans to enroll 415 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.